Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: GlobeNewswire
ANN ARBOR, Mich., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 26, 2020, the Compensation Committee of Esperion’s Board of Directors granted non-qualified stock options to purchase an aggregate of 10,900 shares of its common stock and 59,291 restricted stock units (RSUs) to 149 new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The options have an exercise price of $57.05 per share, which is equal to the closing price of Esperion’s common stock on February 26, 2020. Each option and RSU will vest and become exercisable as to twenty-five percent
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
- Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... [Yahoo! Finance]Yahoo! Finance
- Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y [Yahoo! Finance]Yahoo! Finance
- Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
ESPR
Earnings
- 11/7/24 - Miss
ESPR
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- ESPR's page on the SEC website